Drug intelligence / Profile preview

Tetanus Vaccine (Adsorbed)

Development stage: Approved
Lead developer: Walvax Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Tetanus Vaccine (Adsorbed) is a monovalent vaccine candidate developed by Walvax Biotechnology for active immunization against tetanus. The vaccine is formulated using tetanus toxoid, which is adsorbed onto an aluminum-based adjuvant to enhance its immunogenicity. It works by stimulating the immune system to produce protective neutralizing antibodies against the tetanus toxin produced by *Clostridium tetani*. This standalone product is distinct from Walvax's multi-component vaccines (such as DTaP) and is currently in Phase 2 clinical development.

Brand names: Tetanus Toxoid AdsorbedTDVAXDECAVACTENIVAC
Other names: Tetanus toxoid (adsorbed)

Beyond the preview

Go deeper on Tetanus Vaccine (Adsorbed).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetanus Vaccine (Adsorbed).

Explore the full profile